United Therapeutics reworks deal ahead of a key patent's expiration

Silver Spring drugmaker United Therapeutics Corp. extended an exclusive license with drug giant Eli Lilly& Co. to cover its pulmonary hypertension drug Adcirca, which will lose part of its patent protection later this year. The active ingredient in Adcirca is tadalafil, also the active pharmaceutical ingredient in Cialis, which is marketed by Eli Lilly (NYSE: LLY) to treat erectile dysfunction. United Therapeutics (NASDAQ: UTHR), in 2008, acquired the commercial rights to Adcirca from Eli Lilly…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news